8-K: Dyadic International Secures $3 Million Grant from Gates Foundation for Monoclonal Antibody Development

Dyadic International has received a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effective monoclonal antibodies for respiratory syncytial virus (RSV) and malaria using its C1 protein production platform.

Summary

• Dyadic International has been awarded a $3,092,136 grant from the Bill & Melinda Gates Foundation.
• The grant will fund the development of monoclonal antibodies targeting RSV and malaria using Dyadic's C1 protein production platform.
• The goal is to create globally accessible and affordable treatment options for underserved populations.
• RSV causes over 3.2 million hospitalizations and 100,000 deaths annually, with 99% of these occurring in low-income and middle-income countries.
• In 2022, there were an estimated 249 million malaria cases and 608,000 malaria deaths globally, with the WHO African Region accounting for 94% of cases and 95% of deaths.
• The C1 platform aims to reduce production costs and improve the scalability of biologic vaccines and therapeutics.
• Dyadic plans to commercialize these antibodies through licensing if research efforts are successful.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant grant received from a reputable organization, the focus on addressing critical global health issues, and the potential of the C1 platform to make a meaningful impact.

Positives

• The grant provides significant funding for Dyadic to advance its C1 platform.
• The focus on RSV and malaria addresses critical global health needs.
• The C1 platform has the potential to make monoclonal antibodies more affordable and accessible.
• The project aligns with Dyadic's mission to develop cost-effective therapeutics.
• The collaboration with the Gates Foundation enhances Dyadic's credibility and visibility.

Risks

• The success of the project depends on the effectiveness of the C1 platform in producing the required antibodies.
• There are risks associated with the development and commercialization of new therapeutics.
• The project is subject to the terms and conditions of the grant agreement.
• The company's forward looking statements are subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

Dyadic plans to commercialize the developed antibodies through licensing, expanding access to affordable treatment options and reducing the global burden of infectious diseases, if research efforts are successful.

Management Comments

• Mark Emalfarb, Founder and CEO of Dyadic, stated that the grant will advance their C1 platform to develop affordable therapeutics for RSV and malaria.
• He believes C1's increased efficiency and cost-effectiveness can expand access to therapeutics and vaccines for populations impacted by health disparities.

Industry Context

This announcement highlights the growing need for affordable and accessible therapeutics, particularly in lowand middle-income countries. It also underscores the importance of innovative protein production platforms like Dyadic's C1 in addressing global health challenges.

Comparison to Industry Standards

• The development of monoclonal antibodies is a competitive field, with companies like Regeneron, Eli Lilly, and AstraZeneca also working on similar treatments.
• Dyadic's C1 platform aims to differentiate itself through cost-effectiveness and scalability, which are crucial for addressing the needs of LMICs.
• The Gates Foundation's investment in Dyadic suggests confidence in their approach to producing affordable biologics.
• The focus on RSV and malaria aligns with global health priorities and the efforts of organizations like the WHO.

Stakeholder Impact

• Shareholders will likely view the grant positively, as it validates Dyadic's technology and provides funding for future development.
• Employees may be motivated by the opportunity to contribute to a project with significant global health impact.
• Customers and partners may see the grant as a sign of Dyadic's commitment to innovation and quality.
• The project aims to benefit underserved populations by providing access to affordable treatments.

Next Steps

• Dyadic will proceed with the cell line development of monoclonal antibodies targeting RSV and malaria.
• The company will work towards the milestones and deliverables outlined in the grant agreement.
• Dyadic will continue to collaborate with other organizations to develop innovative vaccines and treatments.

Key Dates

Keywords

monoclonal antibodies, C1 platform, Bill & Melinda Gates Foundation, RSV, malaria, global health, therapeutics, biotechnology, protein production, vaccines